Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.
What happened
FDA reviewed Prime Sciences' website from January to March 2026 and found the company offering Cagrilintide, GLP1-R, GLP1-S, GLP1-T, Mazdutide, and BAC water for sale in the United States. FDA said the website labeling includes weight-loss, diabetes, insulin, and blood-sugar claims, showing the products are intended as human drugs despite "research purposes only" statements. FDA also said BAC water was sold in a reconstitution kit with a syringe alongside injectable peptides.
What FDA found
The company offers Cagrilintide, GLP1-R, GLP1-S, GLP1-T, Mazdutide, and BAC water for sale as drugs without an FDA-approved application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The company ships or offers these products across state lines, which the law prohibits for drugs lacking FDA approval.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Website labeling includes claims about weight loss, diabetes, insulin, and blood sugar, so the products are intended as drugs for human use despite research-only statements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128These products are new drugs under the law because they are not generally recognized as safe and effective for their labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)BAC water is a drug because it is sold with a syringe in a reconstitution kit alongside injectable peptide drugs, showing it is intended for injection use.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks Prime Sciences to notify it in writing within 15 working days of steps taken to correct the violations, with an explanation and supporting documents. If correction cannot be completed in that time, FDA asks for the reason and a completion date.
Who should pay attention
- peptide e-commerce sellers
- weight-loss clinics or med spas that recommend injectable peptides
- consumers buying research-labeled peptides online
This is a summary. Read the original letter on fda.gov.